Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

North America is projected to remain the largest ATTR market, holding 46% of global share in 2025, with the U.S. market growing from $3.55B to $13.49B by 2035. Europe is expected to expand from $2.34B to $8.63B over the same period, supported by broader ATTR diagnosis programs, advanced imaging, and increased adoption of RNAi therapies.

Analysis

The investable signal here is not the headline TAM expansion itself, but the shift in the bottleneck from drug discovery to patient finding. In ATTR, earlier identification tends to benefit the company that can convert a newly diagnosed patient fastest into therapy, while also creating incremental volume for imaging and specialty testing; that makes the first-order winners likely to be the RNAi franchise leader and the broader cardiology diagnostics stack.

The market may be underestimating how slow the funnel is from program rollout to reimbursed treatment. Screening, imaging capacity, and referral behavior are the gating items, so revenue inflection is usually measured in quarters to years, not weeks; this means near-term consensus can overshoot while the 12-18 month structural effect remains intact. A second-order risk is payer pushback: as diagnosis rates rise, apparent prevalence expands, which can trigger tougher prior auth and step therapy, especially if real-world persistence is weaker than label-based assumptions.

Contrarian view: the biggest beneficiary may not be the incumbent with the largest current ATTR share, but the platform that can win earlier-line diagnosis and capture treatment-naive patients before specialists anchor on legacy therapy. That argues for watching prescription momentum, new-start share, and imaging utilization rather than just market-size projections. If those metrics fail to accelerate within the next 2-3 quarters, the market is likely overpricing a smooth adoption curve.

Key Decisions for Investors

• Long ALNY on a 3-6 month horizon into the diagnosis-rollout cycle; thesis is share capture from earlier identification, with upside if new starts and persistence data confirm broader adoption. Falsifier: flat quarterly prescription growth or payer compression of net price.
• Pair trade: long ALNY / short PFE for 6-12 months to isolate RNAi adoption versus the mature ATTR incumbent. Best risk/reward if new-patient share shifts before broader market rerating; cover if Pfizer defends share with label expansion, better adherence, or pricing actions.
• Watchlist, not immediate trade: long GEHC or SI (Siemens Healthineers) on any evidence that advanced cardiac imaging utilization is inflecting. This is a volume story, but only if reimbursement and referral rates rise; otherwise the catalyst stays too diffuse.
• Use XLV as a hedge if taking single-name exposure to ATTR leaders: the catalyst is company-specific, but sector multiples can compress if payers broadly tighten specialty-drug access.